InfertilityNCT03147872
Evaluation of the Impact of Reduced Oxygen Concentration on Live Birth Rate
A study testing 2% Oxygen in people with Infertility, run by Reproductive Medicine Associates of New Jersey at 1 site in United States.
Trial summary
Clinical in vitro fertilization relies on successful embryo culture. The primary goal of embryo culture is to attempt to recapitulate the in vivo conditions as much as possible. In the past decade, the majority embryo culture has been performed at 5% oxygen due to the discovery that the oxygen tension in the fallopian… Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Infertility
- What is being tested?
- 2% Oxygen
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 280 participants
- Where
- 1 siteUnited States
- Study dates
- 15 May 2017to 31 Jan 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Anti-mullerian hormone level (AMH) > 1.0 ng/mL
- Must have at least one surviving embryo on day three of development
- Male partner with >100,000 total motile spermatozoa per ejaculate (donor sperm acceptable)
- Body Mass Index < 35
Who cannot join
- Diagnosis of endometrial insufficiency, as defined by prior cycle with maximal endometrial thickness <6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), or persistent endometrial fluid
- Use of oocyte donation
- Use of gestational carrier
- Use of sperm obtained via surgical procedure
- Presence of hydrosalpinges that communicate with endometrial cavity
- Single gene disorders, chromosomal translocations or any other disorders requiring more detailed embryo genetic analysis
Show all 9Show fewer
- Couples seeking gender selection for family balancing
- Completion of the protocol requires a single embryo transfer of an embryo as part of the study. Thus, patients pursuing embryo banking cycles will be excluded from the study.
- Double embryo transfer
Trial locations and contacts
1 site in 1 country.
United States1 site
Reproductive Medicine Associates of New Jersey
Basking Ridge, New Jersey, 07920
About this study
Official title: Lo2 Phase II: A Comparison of Live Birth Rates Between Embryos Cultured in 2% vs. 5% After Day 3 of Embryo Culture
Clinical in vitro fertilization relies on successful embryo culture. The primary goal of embryo culture is to attempt to recapitulate the in vivo conditions as much as possible. In the past decade, the majority embryo culture has been performed at 5% oxygen due to the discovery that the oxygen tension in the fallopian tube (where the embryo is located for the first 3 days after fertilization) is 5%. However, relatively recent studies have demonstrated that the oxygen tension in the uterus (where the embryo is located after day 3) is closer to 2%. This study is a randomized controlled trial that will compare pregnancy rates between embryos cultured in 2% versus 5% after day 3 of development.
Read the detailed description
Significant progress has been made in characterizing the optimal environment for a developing embryo in culture. These efforts have been based on the premise that clinical embryo culture should mimic the in vivo environment. To this end, investigators have gone to great lengths to recreate every aspect of the natural setting to which the early embryo is exposed. This focused approach has led to significant modifications of the embryo culture system in the modern in vitro fertilization (IVF) lab and ultimately to improvements in pregnancy rates.
One area that has been subject to significant scrutiny is the relationship between incubator oxygen concentration and early embryonic development. Oxygen plays a central role in embryonic metabolism. The mechanism governing its utilization is dependent on the stage of embryonic development. During the first 3 days of development, oxygen reaches the embryo via passive diffusion and its concentration gradient is regulated by oxygen consumption during oxidative phosphorylation. Inefficiencies in this process - due to compromised integrity of the inner mitochondrial membrane or alterations in substrate availability - can result in excessive production of harmful reactive oxygen species which can cause significant damage to cellular machinery and ultimately lead to embryonic arrest.
The concentration of oxygen that the embryo in culture is exposed to can also impact this delicately balanced system and alter the metabolic health of an embryo. Historically, atmospheric oxygen concentration (approximately 20%) was exclusively used in human IVF laboratories for embryo culture. However, multiple investigations subsequently found that the physiologic concentration of oxygen within the female reproductive tract is well below atmospheric levels, being consistently measured at <10%. These observations led to multiple trials comparing atmospheric oxygen concentrations to 5% oxygen in embryo culture. These studies demonstrated significant perturbations in gene expression, protein secretion, and suboptimal utilization of amino acids and carbohydrates in embryos cultured in atmospheric oxygen. The same comparisons were made in clinical IVF studies and demonstrated that embryos cultured in 5% oxygen consistently resulted in an increase in clinical pregnancy rate and live birth rate. A meta-analysis of this topic suggested that a clinic with a baseline live birth rate of 30% could expect an improvement as great as 13% when culturing embryos at 5% O2.
As a result of these compelling data, most modern IVF programs now exclusively culture embryos at 5% oxygen concentration. However, some have proposed that the oxygen concentration to which the embryo is exposed after day 3 of development is actually lower than 5%. These data originate from the idea that the embryo crosses the utero-tubal junction on day 3 of development in vivo. Multiple studies have demonstrated that the oxygen concentration in the uterus is actually lower than that in the fallopian tube at approximately 2%. Thus, the most physiologic embryo culture system would culture embryos in 5% oxygen until day 3 and then decrease the oxygen concentration to 2% until transfer or cryopreservation on day 5 or 6.
A change in the optimal oxygen concentration for an embryo on day 3 would fit with a general shift in metabolic requirements of embryos seen at this stage of development. Activation of the embryonic genome occurs on day 3 which prompts a significant increase in biosynthetic activity. The metabolic behavior of embryos also shifts substantially during this time. The embryo changes its metabolic strategy from oxidative phosphorylation to glucose based metabolism in the form of the aerobic glycolysis and the citric acid cycle. During this process, termed compaction, embryos exhibit greatly increased oxygen consumption.
The physiologic environment of the female reproductive tract tends to mirror the metabolic needs of the developing preimplantation embryo. As the embryo shifts its metabolic strategy after compaction and upon entering the uterus, it is certainly possible that a reduced oxygen concentration in the uterus may best support the energy producing mechanisms of this stage in embryonic development. Recapitulating this environment in culture may enhance embryonic development and long term health of pregnancies resulting from IVF.
This theory has been corroborated in two recent pilot studies. The first study, recently awarded the Prize Paper Award at the 2016 American Society for Reproductive Medicine Scientific Meeting, randomized embryos donated to research to 2% or 5% oxygen concentration after day 3 of development and found that embryos were twice as likely to blastulate if they were cultured in 2% oxygen concentration. However, embryos studied in this investigation were either abnormally fertilized or warmed from cryopreservation on day 3 after being donated to research. None were intended for clinical use.
With these limitations in mind, our group has recently completed a study utilizing embryos intended for clinical use (Copernicus IRB: RMA-2016-02). In this study, we enrolled 60 patients and split all ongoing embryos on day 3 of development to culture in either 2% or 5% oxygen until the blastocyst stage. The results have not yet been published, but culture in 2% oxygen after day 3 produced more blastocysts than culture in 5% oxygen. In total, 30 patients had more embryos reach blastocyst in 2% oxygen, while only 17 patients had more embryos reach blastocyst in 5% oxygen. Ten patients had an equal number in both conditions (3 withdrew from the study). This difference reached statistical significance.
This initial study was designed to specifically evaluate the developmental performance of embryos in both conditions. However, there are also some pregnancy data available from those patients who have proceeded to transfer these embryos. In this initial study, culture conditions had no impact on the decision of which embryo to transfer. This was blinded to embryologists and patients and only typical morphology criteria were utilized. Again, of patients who have proceeded to embryo transfer, embryos that had been cultured in 2% oxygen have performed better than those exclusively in 5% (88.9% [16/18] vs. 62.5% [15/24]
However, this initial study was not designed to specifically test the question of whether 2% versus 5% oxygen in extended culture produces better pregnancy outcomes. The patients were not randomized to either 2% or 5% oxygen. Thus, current pregnancy data is prone to some bias and a better controlled study is needed evaluate the impact of reduced oxygen concentration in culture on the most important outcomes: live birth rate.
Purpose of Proposed Study This study seeks to compare clinical outcomes of embryos cultured at 2% oxygen concentration and 5% oxygen concentration after compaction. The primary outcome under study will be live birth rate. Secondary outcomes will include miscarriage rate, gestational age at delivery, birth weight at delivery, embryo blastulation rate, embryo ploidy status (aneuploid or euploid) and morphologic parameters (expansion, inner cell mass grade, trophectoderm grade). The cumulative live birth rate of all embryos that originate from the study stimulation cycle will also be collected and analyzed. This will theoretically reveal whether any advantage in the number of available blastocysts for transfer translates to greater reproductive efficiency when extended culture is performed at 2% oxygen.
- Conditions
- Infertility
- Being tested
- 2% Oxygen
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2% OxygenOther
2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
| Study group | Role | What they receive |
|---|---|---|
| 5% Oxygen | No intervention | All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol). |
| 2% Oxygen | Experimental | All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria). Receives: Other: 2% Oxygen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Live Birth Rate
Delivery of a fetus after 20 weeks of gestation (WHO definition)
Measured: through study completion, an average of 1 year
Secondary outcomes (7)
Miscarriage Rate
Number of pregnancy losses after visualization of a gestational sac and yolk sac on ultrasound
Measured: through study completion, an average of 1 year
Gestational Age at delivery
The number of weeks gestation completed prior to delivery of the fetus
Measured: through study completion, an average of 1 year
Birthweight at delivery
Weight in grams of fetus at time of delivery
Measured: through study completion, an average of 1 year
Embryo blastulation rate
Number of embryos that progress to the blastocyst developmental stage per fertilized ova
Measured: through study completion, an average of 1 year
Embryo ploidy status
The percentage of embryos that are deemed euploidy by preimplantation genetic screening
Measured: through study completion, an average of 1 year
Embryo morphologic parameters
Assignment of morphologic grade of embryos (as per modified Gardner's criteria)
Measured: through study completion, an average of 1 year
Cumulative live birth rate
The number of live births (per definition above) achieved from all embryos derived from the in vitro fertilization cycle involved in the study for a given patient
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2017
- Study start15 May 2017
- Primary completion31 Dec 2020
- Study completion31 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Controlled Trial
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 280 participants (actual)
Sponsor and investigators
- Lead sponsor
- Reproductive Medicine Associates of New Jersey
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto Universitario IVI
- Responsible party
- Sponsor
- Investigators
- Scott Morin, MD, Principal investigator, Reproductive Medicine Associates of New JerseyDaniel J Kaser, MD, Principal investigator, Reproductive Medicine Associates of New Jersey
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03147872
- Sponsor's protocol ID
- RMA-2017-02
- Status last verified
- May 2021
- First submitted
- 8 May 2017
- Last updated
- 19 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Fischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys, hamsters and rabbits. J Reprod Fertil. 1993 Nov;99(2):673-9. doi: 10.1530/jrf.0.0990673.
PubMed 8107053Bontekoe S, Mantikou E, van Wely M, Seshadri S, Repping S, Mastenbroek S. Low oxygen concentrations for embryo culture in assisted reproductive technologies. Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008950. doi: 10.1002/14651858.CD008950.pub2.
PubMed 22786519Gardner DK, Wale PL. Analysis of metabolism to select viable human embryos for transfer. Fertil Steril. 2013 Mar 15;99(4):1062-72. doi: 10.1016/j.fertnstert.2012.12.004. Epub 2013 Jan 8.
PubMed 23312219Rinaudo PF, Giritharan G, Talbi S, Dobson AT, Schultz RM. Effects of oxygen tension on gene expression in preimplantation mouse embryos. Fertil Steril. 2006 Oct;86(4 Suppl):1252-65, 1265.e1-36. doi: 10.1016/j.fertnstert.2006.05.017.
PubMed 17008149Meintjes M, Chantilis SJ, Douglas JD, Rodriguez AJ, Guerami AR, Bookout DM, Barnett BD, Madden JD. A controlled randomized trial evaluating the effect of lowered incubator oxygen tension on live births in a predominantly blastocyst transfer program. Hum Reprod. 2009 Feb;24(2):300-7. doi: 10.1093/humrep/den368. Epub 2008 Oct 16.
PubMed 18927130
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lo2 Phase II: A Comparison of Live Birth Rates Between Embryos Cultured in 2% vs. 5% After Day 3 of Embryo Culture
- ClinicalTrials.gov ID
- NCT03147872
- Acronym / sponsor ID
- RMA-2017-02
- Conditions
- Infertility
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 280 participants (actual)
- Lead sponsor
- Reproductive Medicine Associates of New JerseyUniversity, hospital or other
- Collaborators
- Instituto Universitario IVI
- Study start
- 15 May 2017 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Jan 2021 (actual)
- First posted
- 10 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinical in vitro fertilization relies on successful embryo culture. The primary goal of embryo culture is to attempt to recapitulate the in vivo conditions as much as possible. In the past decade, the majority embryo culture has been performed at 5% oxygen due to the discovery that the oxygen tension in the fallopian tube (where the embryo is located for the first 3 days after fertilization) is 5%. However, relatively recent studies have demonstrated that the oxygen tension in the uterus (where the embryo is located after day 3) is closer to 2%. This study is a randomized controlled trial that will compare pregnancy rates between embryos cultured in 2% versus 5% after day 3 of development.
Detailed description
Significant progress has been made in characterizing the optimal environment for a developing embryo in culture. These efforts have been based on the premise that clinical embryo culture should mimic the in vivo environment. To this end, investigators have gone to great lengths to recreate every aspect of the natural setting to which the early embryo is exposed. This focused approach has led to significant modifications of the embryo culture system in the modern in vitro fertilization (IVF) lab and ultimately to improvements in pregnancy rates.
One area that has been subject to significant scrutiny is the relationship between incubator oxygen concentration and early embryonic development. Oxygen plays a central role in embryonic metabolism. The mechanism governing its utilization is dependent on the stage of embryonic development. During the first 3 days of development, oxygen reaches the embryo via passive diffusion and its concentration gradient is regulated by oxygen consumption during oxidative phosphorylation. Inefficiencies in this process - due to compromised integrity of the inner mitochondrial membrane or alterations in substrate availability - can result in excessive production of harmful reactive oxygen species which can cause significant damage to cellular machinery and ultimately lead to embryonic arrest.
The concentration of oxygen that the embryo in culture is exposed to can also impact this delicately balanced system and alter the metabolic health of an embryo. Historically, atmospheric oxygen concentration (approximately 20%) was exclusively used in human IVF laboratories for embryo culture. However, multiple investigations subsequently found that the physiologic concentration of oxygen within the female reproductive tract is well below atmospheric levels, being consistently measured at <10%. These observations led to multiple trials comparing atmospheric oxygen concentrations to 5% oxygen in embryo culture. These studies demonstrated significant perturbations in gene expression, protein secretion, and suboptimal utilization of amino acids and carbohydrates in embryos cultured in atmospheric oxygen. The same comparisons were made in clinical IVF studies and demonstrated that embryos cultured in 5% oxygen consistently resulted in an increase in clinical pregnancy rate and live birth rate. A meta-analysis of this topic suggested that a clinic with a baseline live birth rate of 30% could expect an improvement as great as 13% when culturing embryos at 5% O2.
As a result of these compelling data, most modern IVF programs now exclusively culture embryos at 5% oxygen concentration. However, some have proposed that the oxygen concentration to which the embryo is exposed after day 3 of development is actually lower than 5%. These data originate from the idea that the embryo crosses the utero-tubal junction on day 3 of development in vivo. Multiple studies have demonstrated that the oxygen concentration in the uterus is actually lower than that in the fallopian tube at approximately 2%. Thus, the most physiologic embryo culture system would culture embryos in 5% oxygen until day 3 and then decrease the oxygen concentration to 2% until transfer or cryopreservation on day 5 or 6.
A change in the optimal oxygen concentration for an embryo on day 3 would fit with a general shift in metabolic requirements of embryos seen at this stage of development. Activation of the embryonic genome occurs on day 3 which prompts a significant increase in biosynthetic activity. The metabolic behavior of embryos also shifts substantially during this time. The embryo changes its metabolic strategy from oxidative phosphorylation to glucose based metabolism in the form of the aerobic glycolysis and the citric acid cycle. During this process, termed compaction, embryos exhibit greatly increased oxygen consumption.
The physiologic environment of the female reproductive tract tends to mirror the metabolic needs of the developing preimplantation embryo. As the embryo shifts its metabolic strategy after compaction and upon entering the uterus, it is certainly possible that a reduced oxygen concentration in the uterus may best support the energy producing mechanisms of this stage in embryonic development. Recapitulating this environment in culture may enhance embryonic development and long term health of pregnancies resulting from IVF.
This theory has been corroborated in two recent pilot studies. The first study, recently awarded the Prize Paper Award at the 2016 American Society for Reproductive Medicine Scientific Meeting, randomized embryos donated to research to 2% or 5% oxygen concentration after day 3 of development and found that embryos were twice as likely to blastulate if they were cultured in 2% oxygen concentration. However, embryos studied in this investigation were either abnormally fertilized or warmed from cryopreservation on day 3 after being donated to research. None were intended for clinical use.
With these limitations in mind, our group has recently completed a study utilizing embryos intended for clinical use (Copernicus IRB: RMA-2016-02). In this study, we enrolled 60 patients and split all ongoing embryos on day 3 of development to culture in either 2% or 5% oxygen until the blastocyst stage. The results have not yet been published, but culture in 2% oxygen after day 3 produced more blastocysts than culture in 5% oxygen. In total, 30 patients had more embryos reach blastocyst in 2% oxygen, while only 17 patients had more embryos reach blastocyst in 5% oxygen. Ten patients had an equal number in both conditions (3 withdrew from the study). This difference reached statistical significance.
This initial study was designed to specifically evaluate the developmental performance of embryos in both conditions. However, there are also some pregnancy data available from those patients who have proceeded to transfer these embryos. In this initial study, culture conditions had no impact on the decision of which embryo to transfer. This was blinded to embryologists and patients and only typical morphology criteria were utilized. Again, of patients who have proceeded to embryo transfer, embryos that had been cultured in 2% oxygen have performed better than those exclusively in 5% (88.9% [16/18] vs. 62.5% [15/24]
However, this initial study was not designed to specifically test the question of whether 2% versus 5% oxygen in extended culture produces better pregnancy outcomes. The patients were not randomized to either 2% or 5% oxygen. Thus, current pregnancy data is prone to some bias and a better controlled study is needed evaluate the impact of reduced oxygen concentration in culture on the most important outcomes: live birth rate.
Purpose of Proposed Study This study seeks to compare clinical outcomes of embryos cultured at 2% oxygen concentration and 5% oxygen concentration after compaction. The primary outcome under study will be live birth rate. Secondary outcomes will include miscarriage rate, gestational age at delivery, birth weight at delivery, embryo blastulation rate, embryo ploidy status (aneuploid or euploid) and morphologic parameters (expansion, inner cell mass grade, trophectoderm grade). The cumulative live birth rate of all embryos that originate from the study stimulation cycle will also be collected and analyzed. This will theoretically reveal whether any advantage in the number of available blastocysts for transfer translates to greater reproductive efficiency when extended culture is performed at 2% oxygen.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Randomized Controlled Trial
| Arm | Type | Receives |
|---|---|---|
| 5% Oxygen | No intervention | –All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol). |
| 2% Oxygen | Experimental | Other: 2% OxygenAll patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria). |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Anti-mullerian hormone level (AMH) > 1.0 ng/mL
- Must have at least one surviving embryo on day three of development
- Male partner with >100,000 total motile spermatozoa per ejaculate (donor sperm acceptable)
- Body Mass Index < 35
Key exclusion criteria (9 listed)
- Diagnosis of endometrial insufficiency, as defined by prior cycle with maximal endometrial thickness <6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), or persistent endometrial fluid
- Use of oocyte donation
- Use of gestational carrier
- Use of sperm obtained via surgical procedure
- Presence of hydrosalpinges that communicate with endometrial cavity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2% Oxygen2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development | Other | 2% Oxygen |
Primary outcome
Live Birth Rate
Time frame: through study completion, an average of 1 year
Delivery of a fetus after 20 weeks of gestation (WHO definition)
7 secondary outcomes
Miscarriage Rate
Time frame: through study completion, an average of 1 year
Gestational Age at delivery
Time frame: through study completion, an average of 1 year
Birthweight at delivery
Time frame: through study completion, an average of 1 year
Embryo blastulation rate
Time frame: through study completion, an average of 1 year
Embryo ploidy status
Time frame: through study completion, an average of 1 year
Embryo morphologic parameters
Time frame: through study completion, an average of 1 year
Cumulative live birth rate
Time frame: through study completion, an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2021.
- Background: PubMed 8107053Fischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys, hamsters and rabbits. J Reprod Fertil. 1993 Nov;99(2):673-9. doi: 10.1530/jrf.0.0990673.
- Background: PubMed 22786519Bontekoe S, Mantikou E, van Wely M, Seshadri S, Repping S, Mastenbroek S. Low oxygen concentrations for embryo culture in assisted reproductive technologies. Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008950. doi: 10.1002/14651858.CD008950.pub2.
- Background: PubMed 23312219Gardner DK, Wale PL. Analysis of metabolism to select viable human embryos for transfer. Fertil Steril. 2013 Mar 15;99(4):1062-72. doi: 10.1016/j.fertnstert.2012.12.004. Epub 2013 Jan 8.
- Background: PubMed 17008149Rinaudo PF, Giritharan G, Talbi S, Dobson AT, Schultz RM. Effects of oxygen tension on gene expression in preimplantation mouse embryos. Fertil Steril. 2006 Oct;86(4 Suppl):1252-65, 1265.e1-36. doi: 10.1016/j.fertnstert.2006.05.017.
- Background: PubMed 18927130Meintjes M, Chantilis SJ, Douglas JD, Rodriguez AJ, Guerami AR, Bookout DM, Barnett BD, Madden JD. A controlled randomized trial evaluating the effect of lowered incubator oxygen tension on live births in a predominantly blastocyst transfer program. Hum Reprod. 2009 Feb;24(2):300-7. doi: 10.1093/humrep/den368. Epub 2008 Oct 16.
- Individual participant dataSharing planned: No
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Scott Morin, MD principal investigator
Reproductive Medicine Associates of New Jersey
Daniel J Kaser, MD principal investigator
Reproductive Medicine Associates of New Jersey
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 2% Oxygen in people with Infertility, run by Reproductive Medicine Associates of New Jersey at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Live Birth Rate (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03147872, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2021.